Kornimate/medical-research-clean huggingface dataset:
cardiovascular remodeling in living kidney donors with reduced glomerular filtration rate

Conditions: Cardiovascular Diseases

Summary: chronic kidney disease (ckd) is highly frequent, and patients with advanced ckd are known to have a high risk of developing cardiovascular disease (cvd). however, little is known about the cardiovascular risk in patients with mildly reduced kidney function (reduced glomerular filtration rate, gfr), affecting up to 10% of the general population; and importantly, also affecting living kidney donors. until recently it has been believed that donating a kidney does not represent any health hazard. however, a recent norwegian epidemiological study suggested that kidney donors have an increased risk of cvd. the pathogenesis linking reduced kidney function to cvd is not known. living kidney donors provide a unique model for investigating the mechanisms underlying increased risk of cvd in patients with reduced gfr because living kidney donors are healthy before donation. thus, the main purpose of the project is to investigate the mekanismes underlying the development of cardiovascular remodelling induced by a reduction in gfr.


Eligibility criteria:
* donor group: persons selected as living kidney donors according to the norwegian donor criteria and accepted for surgery at rikshospitalet, norway * control group: persons fulfilling the criteria according to the norwegian transplantation protocol for living kidney donors with one exeption: they do not have to be investigated with ct angiography which is not considered necessary. exclusion criteria: • persons who do not meet the norwegian donor criteria.

Keywords: kidney donor
five versus seven day antibiotic course for the treatment of pneumonia in the intensive care unit

Conditions: Pneumonia, Bacterial

Summary: the goal of the study is to determine if patients who are being treated for pneumonia in the intensive care unit can be safely treated with five days of antibiotics (the current standard is seven to eight days). the goal is to determine if the investigators can minimize antibiotic complications while still treating the infection. patients in the study are randomly assigned to either receive antibiotics for a goal of five days or a goal of seven days. every patient is followed daily, and if they are not responding to the antibiotics, the treating team in the intensive care unit care can continue the antibiotics for a longer course regardless of what group the patient is assigned. the investigator's hypothesis is that patients in the five day treatment goal will be able to receive less antibiotics than patients in the seven day treatment goal without any adverse effects.

this is a pilot study to determine if patients with pneumonia in the intensive care unit can safely receive five days of antibiotics. all patients admitted to the medical and surgical intensive care units at barnes-jewish hospital with pneumonia will be screened for the inclusion and exclusion criteria. patients will be randomized by sealed envelopes in groups of six to a five or seven day course of antibiotics. the choice of the antibiotic to be used is determined by the intensive care unit treating team. the patients will not be randomized to a specific antibiotic. the patients will be followed for a clinical response by improvement in maximum daily temperature, white blood cell count, and pao2 to fio2 ratio. antibiotics can continue past the goal duration for patients in either group if the above criteria are not met or if the attending physician in the intensive care unit feels that a longer course is needed. the treating team in the intensive care unit will not be blinded to the patient's treatment assignment.

Eligibility criteria:
inclusion criteria: * new diagnosis of pneumonia * patient in medical or surgical intensive care unit * age greater or equal than 18 years old exclusion criteria: * neutropenia * recipient of a solid organ or bone marrow transplant * bacteremia * presence of acinetobacter baumannii or stenotrophomonas maltophilia from a respiratory tract culture * presence of a second infection requiring antibiotic therapy * pregnancy * enrollment in another clinical study * patient or surrogate unable to provide informed consent * attending intensive care unit physician declined enrollment in the study

Keywords: pneumonia, bacterial
pharmacologic relapse prevention for alcoholic smokers

Conditions: Alcoholism; Smoking

Summary: this study will compare the long-term use of bupropion (wellbutrin) and placebo for reducing the rate of smoking relapse in recovering alcoholics who achieved initial abstinence from smoking with nicotine patch therapy. the study will also determine the cessation rate in the 8th week of treatment among recovering alcoholics using a nicotine patch. the patch dose is projected to serve as a 100-percent replacement.

the purpose of this trial was to recruit 292 recovering alcoholic smokers (abstinent from alcohol for a minimum of 1 year), who want to stop smoking and provide them with 100% nicotine replacement. the 100% nicotine replacement will be undertaken using a nicotine patch. by measuring their nicotine levels at study entry we can determine the patch dosing needed. the patch dosing will vary from 22 mg to 44 mg. those who are able to achieve tobacco abstinence by week 8 will enter a relapse prevention phase for the remaining 44 weeks. in this phase, they will be randomized to active or placebo bupropion (300 mg/day). after 44 weeks of the relapse prevention trial (at week 52 of study participation), they will enter a post medication follow up for 6 months.

Eligibility criteria:
inclusion criteria: * history of alcohol dependence and at least one year of abstinence from alcohol intake. * has a history of smoking 20 or more cigarettes per day for the prior year. * can read and write english. * stated ability to fully participate in the study and keep all scheduled appointments. * has provided written informed consent. * general good health. exclusion criteria: * recent history (within three months) of a clinically significant myocardial infarction, unstable angina pectoris, serious cardiac arrhythmia or any other medical condition which the physician investigator deems incompatible with study participation. * current major depression. a past history of major depression will not be an exclusionary criteria. * current or previous use of bupropion (wellbutrin). * active non- nicotine drug dependence. * past or current history of bipolar disorder, pain disorder or psychosis, schizophrenia, or other major psychiatric disorders. * current medically indicated use of psychiatric drugs. * females who are pregnant, lactating, or likely to become pregnant during the first year which includes the nicotine patch and bupropion (wellbutrin) phase. * history of severe skin allergies or evidence of severe chronic skin disorders. * current use of nicotine containing medication or tobacco products other than cigarettes. * current use (within 30 days of initiation of patch therapy) of the following medications for smoking cessation: clonidine, buspirone, or doxepin. * a predisposition to seizures. * a history of or current diagnosis of anorexia nervosa or bulimia. * medical disorder that would interfere with the absorption, metabolism, or excretion of bupropion (wellbutrin).
next generation sequencing-based "oncochip" for therapeutic decision in metastatic breast cancer. study sharp

Conditions: Breast Cancer, Metastatic Breast Cancer

Summary: the present trial clinical proposes to randomize patients with cancer metastatic disease of the breast progressing on standard therapy to receive a treatment selected from 4 "targeted" drugs (a mek kinase inhibitor, an mtor kinase inhibitor, an of the enzyme involved in dna repair parp and an androgen receptor inhibitor) on the basis of possible presence of mutations in a panel of 61 genes analyzed on metastatic tissue from biopsy, or receive standard chemotherapy.


Eligibility criteria:
inclusion criteria: * patients (women or men) with histologically confirmed metastatic breast cancer * eastern cooperative oncology group (ecog) performance status 0 or 1 * written informed consent obtained prior to enrollment * age ≥ 18 years * blood and tumor tissue sample available for research * measurable disease * other site accessible for biopsy, except bone lesions if this is the only accessible site, or biopsy obtained within the previous 6 months * medical history, blood parameters and clinical conditions do not indicate major dysfunctions of organ to treatment: - maintenance of screening inclusion criteria exclusion criteria: * presence of visceral crisis, defined according to abc3/esmo guidelines * patients with local recurrence that can be treated with surgery and/or radiotherapy alone * patients who have previously received palliative radiotherapy on the only site accessible to biopsy * patients with metastatic disease limited to bone * patients with metastatic disease limited to the brain, unless planned a surgical excision, in which case tissue can be collected for screening * severe hematopoietic, renal and/or hepatic insufficiency * known contraindication to biopsy * neoplastic pathology of different histology in the previous 5 years, except carcinoma in situ of cervical basal or squamous cell carcinoma of the skin, if adequately treated
non-interventional study for prevention and treatment of fungal infections in paediatric patients in asia/oceania - eradicate study

Conditions: Invasive Fungal Infections

Summary: the aim of the study is to prospectively evaluate the safety and efficacy of micafungin when prescribed for prophylaxis or treatment of fungal infections in different real-world clinical conditions and centers, in pediatric patients in asia/oceania.

the study will collect safety and efficacy data from pediatric patients who are prescribed intravenous micafungin for prophylaxis. during this trial, patients with two separate indications will be treated. the first, invasive candidiasis will have a minimum treatment of 2 weeks. the second, oesophageal candidiasis will have a minimum treatment of 1 week. both indications will have a follow-up period of 4 weeks after treatment.

Eligibility criteria:
inclusion criteria: * prescribed micafungin for prophylaxis or treatment of fungal infections. according to treatment guidelines, micafungin may not be a suitable treatment for the following patients: * the patient has evidence of impaired liver function: alanine aminotransferase (ast), aspartate aminotransferase (alt) \>5 times the upper limit of normal (uln) or total bilirubin \>2 times uln. * the patient has a history of allergy, hypersensitivity, or any serious reaction to the echinocandin class of antifungals. * the patient has a confirmed systemic fungal infection with a non-candida species. exclusion criteria: * the patient is receiving micafungin treatment in combination with other antifungal drugs.

Keywords: oesophageal candidiasis paediatric invasive candidiasis prophylaxis of candida infections candidemia aspergillosis micafungin
evaluation of priming effects by plai vaccine on the subsequent response to inactivated h5n1 vaccine

Conditions: Avian Influenza

Summary: this study aim to compare immunogenicity of the inactivated h5 influenza vaccine single dose between subjects previously vaccinated with laiv h5n2 and naïve subjects

it is a non-randomized, open label study to evaluate a licensed orniflu® inactivated vaccine (produced by microgen russia) which will be given to healthy adult volunteers who participated in a double blind placebo-controlled study protocol no.: gpo avian flu vaccine-v02-2 at vaccine trial centre and department of clinical tropical medicine, faculty of tropical medicine, mahidol university in february to may 2013. a total of 60 subjects, of whom 40 received two doses of laiv h5n2 (prime-boost group), and 20 received placebo (control group) in the previous study will be asked to return to the clinic to receive a single dose of an inactivated h5 influenza vaccine. total foloww up is 90 days.

Eligibility criteria:
inclusion criteria: * participated in the phase ii study protocol no.: gpo avian flu vaccine-v02-2 * healthy * age 18-49 years old * having thai id card or equivalent * anti hiv - negative * all hematology, biochemistry and urine analysis are within normal range or of no clinical significance (not higher than 1.5 time of normal value without any clinical finding from history and physical examination) * able to read and write and sign written informed consent. exclusion criteria: * known history of egg allergy * having had recently influenza infection confirmed as h5 * receiving other vaccination against h5n1 * history of bronchial asthma * history of chronic lung diseases * history of chronic rhinitis * history of immunodeficiency state * history of immunosuppression\< 6 months prior to immunization * history of heavy smoking (more than 5 packs per day) * history of alcoholic (pure drink 200 ml per day) * acute infectious and noninfectious diseases (within 2 weeks) * hiv positives * the volunteers who have been taking immunoglobulin products or have had a blood transfusion during past three months before the beginning of the experiment * participation in other research study or stop participant less than 1 month * pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding * poultry workers

Keywords: h5n2 vaccine
sosteniamoci: an internet-based intervention to support informal caregivers.

Conditions: Caregiver Burden

Summary: the purpose of this study is to evaluate efficacy of internet intervention for informal caregivers in italy in reducing their care-giving burden.

this intervention is going to take a form of an internet-based intervention (ibi) consisting of eight therapeutic modules. these are the themes, as listed chronologically: introduction, thoughts and acceptance, problem solving, stress and relaxation, communication, behavioural activation, worry and anxiety, maintenance. these themes were chosen after considering topics which might be the most useful for someone in a role of an informal caregiver, considering the trans-diagnostic nature of the intervention. effect of the intervention will be compared against a wait-list control group. intervention is in italian.

Eligibility criteria:
inclusion criteria: 1. 18 years old or over and both gender; 2. spent at least the last couple of months providing care; 3. must have internet access and the ability to use a computer or any other compatible device; 4. must be able to complete a phone interview - exclusion criteria: 1) having severe physical or mental impairments, psychiatric conditions or neurological disorders; 2) the person in need of care has a life expectancy below or approximately around 6 months; 3) not able to use a computer or an electronic device; 4) not able to complete a phone interview; -

Keywords: informal caregiver internet-based intervention caregiver burden culturally adapted ehealth
a single-blind placebo run-in study of duloxetine for activity-limiting osteoarthritis pain

Conditions: Osteoarthritis; Pain

Summary: this will be a single-blind, placebo-run-in trial. subjects will be informed that they may receive duloxetine or placebo during the course of the trial. all subjects will, in fact, receive placebo for the first two weeks. all subjects will then be placed on 60-90mg per day of duloxetine. primary outcome assessment will compare pain intensity at 2 weeks (after placebo) to that at 12 weeks (after 10 weeks of duloxetine treatment). study hypothesis: in subjects who continue to have activity-limiting osteoarthritis pain after treatment with acetaminophen or non-steroidal anti-inflammatory agents, 60-90 mg duloxetine per day over 10 weeks will provide significant additional pain relief over that achieved with placebo(\> 30% reduction after duloxetine treatment).


Eligibility criteria:
inclusion criteria: * age 50-80 * physician diagnosis of oa in hip, knee or spine. * significant activity limitation due to pain for at least one month on the western ontario and mcmasters university osteoarthritis index (womac) and average pain \>5/10 on brief pain inventory despite adequate treatment with acetaminophen or nsaids. \[this will identify an oa group with significant psychological distress and a desire for treatment.\] * depression status is not restricted, but will be monitored with prime-md interview and the scl-20. we anticipate depressive symptoms will be common in this population due to the above requirement for activity limitation. exclusion criteria: * cannot read and write english * significant cognitive impairment * history of psychosis or mania * current suicidal ideation * current substance abuse or dependence * current use of opioids or any antidepressant medication * use of investigational drug within the past month

Keywords: osteoarthritis pain activity limitation antidepressant depression single-blind
knowing and treating kosaki/penttinen syndromes

Conditions: Kosaki Overgrowth Syndrome; Penttinen Syndrome

Summary: kosaki overgrowth syndrome (kogs) and penttinen syndrome (ps) are extremely rare multisystem disorders caused by heterozygous activating variants of the pdgfrb gene. kogs results in characteristic craniofacial, orthopedic, skin and neurological disorders. ps is a progeroid disease responsible for a prematurely aged appearance. patients suffer significant morbidity and mortality due to various complications. tyrosine kinase inhibitors (tkis) targeting pgdfrb appear to be a potential treatment option, as evidenced by a few case reports showing clinical improvement in some patients, with modest and self-resolving side effects. the natural history of these two syndromes remains poorly understood as only case-reports have been published. therefore, an international consortium was created in december 2019 by pr faivre (chu dijon bourgogne \& ern ithaca) to follow treated and untreated patients in a real-life, multicentre, observational study, in order to expand our knowledge of these ultra-rare diseases. in the longer term, we believe that tkis could bring clinical benefit to kogs/ps patients.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of kosaki or penttinen syndrome * molecular diagnosis of an activating variant in pdgfrb gene * patient who has been informed and provide a written informed consent exclusion criteria: * absence of clinical diagnosis of kosaki or penttinen syndrome * absence of molecular diagnosis of an activating variant in the pdgfrb gene. * patient who has not been informed and/or did not provide a written informed consent.
in vivo assessment of endodontics procedures

Conditions: Apical Periodontitis

Summary: in view of the wide variety of mechanized endodontic instrumentation systems, the ideal would be that the choose of this system based on the anatomical characteristics of the canal and the biological precepts. in teeth with lesions, contaminated dentin should be removed. however, in many systems, the manufacturer's approach disregards the fact that in wider root canal, instruments used in the apical third small diameter (less than 0.40 mm) may not touch the walls at the final apical. therefore, the establishment of the initial apical file (lai), the first instrument that measures the resistance of the walls in working length, could be a criterion in the choice of which system to use, and how many files work within the root canals after lai determination. however, there is a lack of studies that demonstrate that lai determination affects the degree of cleaning achieved, as well as the impact that lai-based instrumentation may have on microcracks formation, canal transportation, postoperative pain and quality of obturation.in this way, the investigators propose a study in vivo performed, in patients from 8 to 18 years of age, therefore in large root canals. the protocol recommended by the manufacturer will be compared by means of a prospective randomized clinical trial, with the addition of the xp endo finisher and with the protocol based on the initial apical file evaluating postoperative pain, exacerbation between the sessions, the quality of the obturation and periapical radiolucency repair. considering that currently performing endodontic treatments using mechanized instruments is taught in undergraduate courses throughout the country, studies of this nature help the execution of a endodontics more critical and effective.

infected root canal treatments will be performed in two sessions with a tf adaptive system (protocol recommended by manufacturer (group control) vs. protocol based on the initial apical file). the root canals will be completed after 14 days. patients will record postoperative pain during the follow-up period (7 days) using a visual analogue scale (vas) and the change in periapical radiolucency will be assessed by periapical index (pai) scores.

Eligibility criteria:
inclusion criteria: * participants who have in their mandibular or maxillary molar teeth apical periodontitis symptomatic or asymptomatic with apical radiolucence. exclusion criteria: * patients with medical history compromises outcomes * atresic and root canals * root canals with curvature greater than 30 degrees * previously performed endodontics treatment.

Keywords: endodontics, molars, instrumentation, obturation, anatomy
longitudinal study of the default-mode network connectivity in brain injured patients recovering from coma

Conditions: Coma

Summary: several studies in healthy volunteers have suggested that the synchronized functional connectivity in the dmn (deafult-mode network) would sustain the mental content at rest, and when required, a switch in the activity between the dmn and other networks involved in specific congnitive functions, would occur. this interaction permit to make the hypothesis, that baseline brain activity is likely to shape our ongoing " stream of consciousness " and could correlate with conscious perception. the investigators hypothesized that dmn connectivity strength would be related to the level of consciousness of brain-damaged patients. the investigators will follow severely brain-injured patient in coma. clinical examination using standardized behavioural scales: four score (full outline of unresponsivess), coma recovery scale-revised); and brain imaging assessesments using mri (functional and anatomical connectivity, cortical thickness) will be performed at: 3 to 30 (visit 1), and 60 (visit 2) days after insult. if patient recover a normal conscious state between 30 and 60 days, an additional clinical and brain imaging assessment will be performed to identify related changes in brain activity (visit 1\*) monitoring of vital parameters will be performed in patients by a senior anaesthesiologist throughout the experiment.


Eligibility criteria:
inclusion criteria: * brain-damaged patients in coma (trauma or anoxic origin). * male and female, ranging in age from 18 to 75 years. exclusion criteria: * withdrawal of consent from the patients (or the persons having legal responsibility for them). * sedation or general anaesthesia during assessement period (\< 24 hours). * mri contraindications

Keywords: default-mode network difussion tensor imaging cortical thickness coma vegetative state minimally conscious state neural correlate of consciousness